ArticlePLoS pathogens2026
Outer membrane vesicles hijack TIM-1 for cellular uptake.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated multi-omics profiling of gut bacterial extracellular vesicles links cargo composition to host transcriptional responses.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outer membrane vesicles (OMVs) are nanoscale proteoliposomes shed by Gram-negative bacteria that mediate host-pathogen interactions and hold promise as platforms for vaccines and targeted drug delivery. Despite their biological and translational significance, the cellular mechanisms governing OMV entry into host cells remain poorly understood. Here, we demonstrate that E. coli OMVs are internalized by epithelial cells via clathrin-mediated, receptor-dependent endocytosis. Using a high-throughput screen of over 1,500 human single-pass transmembrane proteins, we identify T-cell immunoglobulin and mucin-domain 1 (TIM-1) as a strong OMV-binding receptor. Functional validation revealed that TIM-1 overexpression markedly increased OMV uptake, whereas TIM-1 knockout and antibody-mediated blockade significantly impaired internalization across multiple cell lines. Mechanistic studies demonstrate that TIM-1 binds to lipopolysaccharide (LPS) on the OMV surface via its phosphatidylserine-binding domain. Uptake of OMVs by TIM-1 triggers proinflammatory cytokine production which can be reduced by preventing this interaction. Additionally, OMVs from multiple bacterial species hijack TIM-1 for entry, making it an intriguing antivirulence strategy. Our findings establish TIM-1 as a critical host receptor mediating OMV uptake and provide a novel approach to modulate vesicle-driven pathogenesis and enhance OMV-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.